drugset / Trial / NCT06931145
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Phase 4
Not yet recruiting
50 enrolled
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of benmelstobart in combination with anlotinib and chemotherapy sequential benmelstobart in combination with anlotinib for the first-line treatment of extensive-stage small cell lung cancer.
Timeline
- Start
- 2025-04-15
- Primary completion
- 2027-04-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Catequentinib | Small molecule | 8 mg | Oral |
| Background | Catequentinib | Small molecule | 12 mg | Oral |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |